Regenerative Medical Technology Group net loss widens to US$ 2.91 million in Q2 FY26; revenue rises to US$ 4.02 million

Regenerative Medical Technology Group posted Q2 revenue of US$ 4.02 million, up 309.02% year over year; net loss widened to US$ 2.91 million.

Operating income swung to US$ 565,977 from an operating loss; interest expense climbed to US$ 2.23 million, lifting total other expense.

Business updates included launches of the ISSCA Mobile App on June 17, 2026, and the ISSCA AI Clinical Intelligence Platform on June 23, 2026.

For the six months, revenue rose 183.75% to US$ 6.66 million; net loss widened to US$ 3.22 million.

Cash and cash equivalents increased 38.32% to US$ 1.32 million at June 30, 2026; operating cash flow was US$ 434,098.